Intravenous synthetic peptide MBP8298 delayed disease progression in an HLA Class II-defined cohort of patients with progressive multiple sclerosis: results of a 24-month double-blind placebo-controlled clinical trial and 5 years of follow-up treatment.

Title:

Dataset

identifier:	1663037
description:	epitope description:DENPVVHFFKNIVTPRT antigen name:Myelin basic protein (UniProt:P02686) host organism:Homo sapiens
aggregation:	instance of dataset
availability:	available
primaryPublications:	16879301

Access

authorizations:	registration not required
accessURL:	http://www.iedb.org/reference/1015365
landingPage:	http://www.iedb.org/assay/1663037

Publication

type:	Literature
publicationVenue:	Eur J Neurol
dates:	2006

Dimension

study type:	b cell assays
subject species:	Homo sapiens

Person

fullName:	K G Warren I Catz L Z Ferenczi M J Krantz

Data Type

method:	in vivo assay

Study

name:	Intravenous synthetic peptide MBP8298 delayed disease progression in an HLA Class II-defined cohort of patients with progressive multiple sclerosis: results of a 24-month double-blind placebo-controlled clinical trial and 5 years of follow-up treatment.
description:	In a placebo-controlled double-blinded Phase II clinical trial, the epitope did not reduce disease progression in 32 patients with progressive multiple sclerosis. However, in a subpopulation of patients, those with possessing DR2 and/or DR4 alleles (n=20), disease progression was significantly reduced by treatment with the epitope. In these patients, anti-MBP autoantibodies was reduced.

Data Repository

name:	iedb
homePage:	http://www.iedb.org

Feedback?

If you are having problems using our tools, or if you would just like to send us some feedback, please post your questions on Feedback.